Helsinn Healthcare S.A. v. Dr. Reddy's Laboratories, Ltd. et al.

I'll research this case and the underlying litigation family.

Case overview — Helsinn Healthcare S.A. v. Dr. Reddy's Laboratories, Ltd., No. 2:14-cv-04274 (D.N.J.)

The parties. Helsinn Healthcare S.A. is a privately held Swiss specialty pharmaceutical company (Lugano-Pazzallo) that in 1998 in-licensed palonosetron — a second-generation 5-HT₃ receptor antagonist — from Roche Palo Alto LLC (successor to Syntex), which had run the early Phase I/II work; Roche Palo Alto appears as co-plaintiff and co-assignee on the patents. Helsinn is an operating innovator, not an NPE/PAE, and it does not manufacture or distribute in the U.S. itself: it commercialized Aloxi® through a U.S. partner, MGI Pharma (the 2001 license/supply agreements at the center of the Helsinn v. Teva on-sale-bar fight; MGI was later absorbed into Eisai's U.S. oncology business). Both plaintiffs are repeat, well-resourced Hatch-Waxman plaintiffs represented by Paul Hastings (Helsinn) and Loeb & Loeb (Roche), with Saul Ewing as local counsel. Defendants are Dr. Reddy's Laboratories, Ltd. (Hyderabad, India) and its wholly owned U.S. subsidiary Dr. Reddy's Laboratories, Inc. (Bridgewater, N.J.) — a large Indian generics manufacturer that had already consented to personal jurisdiction in the earlier D.N.J. palonosetron suits.

The accused product. Unlike the companion ANDA cases, this is a § 505(b)(2) "paper NDA" case: DRL filed NDA No. 203050 for palonosetron hydrochloride injection, 0.25 mg/5 mL and 0.075 mg/1.5 mL, relying on FDA's prior findings for Aloxi rather than on full new clinical studies. The formulation is deliberately not a clone — per FDA's review, DRL uses sodium acetate in place of Aloxi's sodium citrate and omits EDTA (with a biowaiver rather than an in vivo

I'll research this case across the docket, opinions, PTAB, and legal press.

Key nuance found: 14-4274 was consolidated into the 505(b)(2) case 12-2867. Let me dig into the docket, IPRs, and final disposition.

Now let me pin down the docket structure, the appeal, and the PTAB proceedings on the '980.

I'll research press coverage of this specific case from multiple angles.

Let me dig into the specific case, docket, and the 2017 ruling.

Let me pin down the docket history and locate more trade-press coverage.

Press coverage of Helsinn Healthcare v. Dr. Reddy's (D.N.J. 14-4274)

What was reported about the ruling. The only dedicated article I located on the merits decision is trade-press coverage of the February 14, 2017 bench opinion. Life Sciences IP Review reported that the District of New Jersey "found that a generic version of Helsinn Healthcare's drug Aloxi (palonosetron) that was proposed by Dr Reddy's infringes three patents for the drug" — U.S. 7,947,724, 8,729,094 and 9,066,980 — and that the court "also rejected Dr Reddy's argument that two of the patents are invalid," quoting the opinion's conclusion that the asserted claims were infringed and "not invalid for lack of written description [or] lack of enablement." The same piece noted the procedural shape of the dispute: Helsinn asserted 13 claims across the patents, Dr. Reddy's contested infringement of three and validity of the other ten while stipulating it would infringe those ten if valid. Dr. Reddy's own press release, issued from Hyderabad on 2017-02-16, confirmed that the court "found that Dr. Reddy's proposed palonosetron hydrochloride 0.25 mg / 5 ml product infringes certain claims of U.S. Patent Nos. 7,947,724, 8,729,094 and 9,066,980, and that the asserted claims of the 094 and 980 Patents were not invalid," and carried a spokesperson statement: "We are disappointed in the decision and intend to pursue an appeal in due course." Notably, no outlet I found reported a damages figure, because none was at issue in this § 271(e)(2)/505(b)(2) action — the reported stakes were regulatory (the date on which Dr. Reddy's could be approved), not monetary.

Financial and market reaction — where coverage went beyond the record. The most substantive reporting came from the Indian financial press, reacting to Dr. Reddy's exchange filing rather than to the opinion itself. Deccan Chronicle reported on 2017-02-16 that Dr. Reddy's shares "fell by nearly 4 per cent," hitting a 52-week low of Rs 2,803.50 on the BSE and Rs 2,798.95 on the NSE. Financial Express reported the same day that the stock "recovered losses and were trading mildly positive after the concerns waned," and supplied market-size estimates not found in any court filing — "The size of the Aloxi drug is estimated to be at $750-800 million globally, and at around $600-650 million in the US alone" — plus analyst commentary: Surajit Pal of Prabhudas Lilladher told CNBC TV18 that a favorable ruling "could have given it an opportunity to launch the drug in the US market" but would not have let Dr. Reddy's "automatically replace[] the original patented drug," since it "would have had to do their own branding and promotion." That framing is analysis and market inference, not court record. The accounts also diverge in an instructive way: both wire-derived stories quote Dr. Reddy's filing as saying "the asserted claims were not valid," which inverts the holding — Dr. Reddy's own release and the February 14, 2017 opinion (Dkt. 232 in consolidated Civ. No. 12-2867, covering 14-4274) state that the claims were not invalid.

The settlement, and how the case actually ended. Coverage of this docket is inseparable from the settlement narrative, and here the primary sources are corporate rather than journalistic. Helsinn announced on 2015-10-13 that it had "entered into a settlement agreement with Dr. Reddy's Laboratories, Inc. to resolve certain patent litigations," under which Dr. Reddy's "will be permitted to market a 505(j) generic version of Aloxi® in the United States on September 30, 2018, or earlier under certain circumstances," with the remaining terms "confidential." Eisai, Helsinn's U.S. marketing partner, repeated on 2015-11-17 that under the settlements "in principle, neither Sandoz nor Dr. Reddy's is allowed to launch a generic version of palonosetron hydrochloride via an ANDA prior to September 30, 2018, except under certain circumstances," and stated that the formulation patents plus pediatric exclusivity gave Aloxi coverage "through to

Sources

• 42. Upon information and belief, Defendant Reddy submitted ANDA
• ANDA 201533
• UNITED STATES PATENT AND TRADEMARK OFFICE
• 41. Plaintiffs reallege paragraphs 1-40 as if fully set forth herein
• DR
• Stewart, A
• NOT FOR PUBLICATION
• HELSINN HEALTHCARE S
• hours
• Melissa E
• 37. Reddy's active and knowing participation in, contribution to, aiding, abetting, and/or inducement of the submission to the F...
• 32. By seeking approval of its NDA to engage in the commercial manufacture, use, sale, offer for sale, and/or importation of gen...

I'll research this docket and the parties' counsel.

Counsel of Record for Plaintiff Helsinn Healthcare S.A. — Helsinn Healthcare S.A. v. Dr. Reddy's Laboratories, Ltd., No. 2:14-cv-04274 (D.N.J.)

Important framing note: this docket is closed (terminated Dec. 5, 2019 per DrugPatentWatch's docket summary for the '094 patent). The complaint (D.I. 1, filed July 7, 2014) was brought by two plaintiffs — Helsinn Healthcare S.A. and Roche Palo Alto LLC — so I list both Helsinn's counsel and Roche's separate counsel (Roche was dismissed by stipulation in 2016). Helsinn's team followed a consistent three-tier structure across the entire ALOXI®/palonosetron litigation family: N.J. local counsel (Saul Ewing), national patent trial counsel (Paul Hastings), and a separate firm for Roche (Loeb & Loeb).

Helsinn Healthcare S.A. — counsel of record

Co-plaintiff Roche Palo Alto LLC — separate counsel (not Helsinn's counsel)

Near-misses worth flagging so they aren't misattributed

• Thomas L. Irving (Finnegan, Henderson, Farabow, Garrett & Dunner, Washington, D.C.) — back-up counsel only in the PTAB proceedings (IPR2015-01554 Notice of Related Matters, July 24, 2015). I found no indication he was counsel of record in 14-4274; Finnegan appears in the palonosetron family as counsel in the Teva appeal papers, not as 14-4274 counsel.
• Naveen Modi (Paul Hastings, Washington, D.C.) — back-up counsel in the '094 IPRs only.
• The govinfo docket metadata for 2:14-cv-04274 also lists names such as Zachary B. Cohen, Alison S. Cooney, Elizabeth E. Grden, Andrew C. Nichols, Maria C. Nunez, Alexander C. Plushanski and Alyssa E. Ramirez. These are attorney names appearing on the docket without party attribution in the metadata I could retrieve; I could not confirm which, if any, were Helsinn's (several are consistent with defense-side firms in the consolidated 14-4274/14-6341 proceedings). I am not attributing them to Helsinn.

Sourcing and limitations

• Verified by primary documents: complaint signature blocks and filed stipulations. The 14-4274 complaint (D.I. 1, filed 7/7/2014, later amended 9/2/2015 to add the '980 patent) is reproduced as Ex. 1006 in IPR2015-01554 and carries the Saul Ewing (Lizza/Baton) and Paul Hastings (O'Malley, Wexler, Dittmann, Conca, Ji, Ni) and Loeb & Loeb (Waddell, for Roche) blocks. The Saul Ewing/Paul Hastings/Loeb & Loeb lineup and the July 26, 2016 Roche dismissal stipulation appear in the 14-4274/14-6341 consolidated filings (D.I. 25 in 14-6341; parallel filing in 14-4274).
• Verified docket events: PI motion practice at D.I. 52 and the opinion denying the preliminary injunction, D.I. 89 (Jan. 30, 2018, Judge Chesler) — Helsinn Healthcare S.A. v. Dr. Reddy's Labs., Ltd., Nos. 14-4274 (SRC), 14-6341 (SRC) (Consol.); final opinion & order Dec. 21, 2018; case terminated Dec. 5, 2019.
• Not verified / could not confirm: I was unable to pull the full PACER docket sheet itself (paywalled), and I found no evidence of any Helsinn in-house attorney entering an appearance in 14-4274 — if one did, it is not reflected in the public filings I could retrieve. No filings in 14-4274 appeared to be sealed as to counsel identity. Firm titles (partner vs. associate) for the Paul Hastings lawyers are inferred from firm/PTAB materials and signature-block ordering rather than a current firm directory, so treat "partner/associate" labels as approximate.
• Useful citation: Helsinn's PTAB power of attorney and related-matters filings in IPR2015-01554 (July 21–24, 2015) list Dittmann as lead and Modi, Irving and Waddell as back-up, which corroborates the district-court/PTAB division of labor above.

I'll research the docket and appearances for the Dr. Reddy's defendants in 14-4274 (and its consolidated parent).

Good initial hits. Now let me pull the actual dockets and appearances for 14-4274.

Let me pull the specific 14-4274 docket and the PTAB representation details.

Counsel of Record — Dr. Reddy's Laboratories, Ltd. & Dr. Reddy's Laboratories, Inc. (D.N.J. 14-4274)

Threshold caveat on the record. Civ. A. No. 14-4274 was filed 7/7/2014 and, per the court's own recitation, was treated as part of the consolidated palonosetron proceeding with No. 12-2867 — "[Helsinn] also brought Civil Case No. 14-4274 in this court asserting infringement of the '094 and '980 patents" (Helsinn Healthcare S.A. v. Dr. Reddy's Labs., Ltd., No. 12-2867 (MLC)(DEA), post-trial opinion, slip op. at 10, cases.justia.com). Because Helsinn and Dr. Reddy's settled on October 6, 2015, and the case was dismissed with a consent judgment/enjoinment (recounted in Sagent's later motion, Helsinn v. Sagent, No. 16-173, D.I. 53 at 17–18, storage.courtlistener.com), Dr. Reddy's counsel of record in 14-4274 were those who appeared in 2014–2015. The later 2018 activity in the 14-4274 docket (the 1/30/2018 preliminary-injunction denial and the 12/21/2018 opinion and order, govinfo) concerned Teva, not DRL — so defense-side appearances in those filings were Teva's counsel (Winston & Strawn), not Dr. Reddy's.

Trial / district-court counsel of record — Budd Larner, P.C. (Short Hills, NJ)

Verification note: I was not able to retrieve a native 14-4274 docket sheet through PACER/CourtListener in this session, so the above is built from (i) the June 15, 2015 trial transcript in the consolidated case (reproduced as an exhibit in IPR2015-01550, docketalarm) and (ii) DRL's signature blocks in 11-3962 (D.I. 174, 178). Those are the same Budd Larner team that represented DRL across the consolidated palonosetron matters (11-3962, 11-5579, 12-2867, 14-4274), but a docket-by-docket appearance check for 14-4274 itself is still outstanding.

PTAB counsel — Lerner David Littenberg Krumholz & Mentlik LLP (LDLKM), Cranford, NJ

These attorneys were DRL's counsel of record before the PTAB, not in the district court:

In-house

• Lee Banks, Esq. — in-house counsel, Dr. Reddy's Laboratories, Inc., 200 Somerset Corporate Blvd., Fl. 7, Bridgewater, NJ. He is identified in Helsinn's complaints (11-5579 / 12-2867 family) as the in-house attorney whom Reddy Ltd. appointed as its agent for service of process in New Jersey. He is not listed as counsel of record in 14-4274.

Things I could not verify (flagged rather than guessed)

1. No confirmed 14-4274-specific appearance list. The Justia docket stub for 3:14-cv-04274 (dockets.justia.com) returns a combined "Represented By" list that mixes plaintiff and defense counsel (Baton, Lizza, Dittmann are Helsinn/Roche-side). One name in that snippet, Sarah Ann Sullivan, I could not confidently attribute to either side — do not treat her as DRL counsel without a docket confirmation.
2. Later-docket names. The govinfo metadata for 14-4274 (mods.xml) indexes a long attorney list including Zachary B. Cohen, Alison S. Cooney, Elizabeth E. Grden, Andrew C. Nichols, Maria C. Nunez, Alexander C. Plushanski, Alyssa E. Ramirez, David Y. Wang, and Dana R. Weir. Most of these are attributable to plaintiff or Teva representation in the 2018 phase (Weir = Paul Hastings/Helsinn; Nichols = Winston & Strawn/Teva). I could not verify any of them as DRL counsel, and I am not asserting they are.
3. Local-versus-national structure. Unlike most ANDA cases here, DRL used Budd Larner (New Jersey) as its district-court lead rather than a national firm with NJ local counsel — i.e., Budd Larner functioned as both lead and